Merck to slash its sales force
- Share via
From Times Wire Services
Drug maker Merck is cutting 1,200 sales jobs in the U.S. following a week of regulatory setbacks for two of its drug candidates.
The job cuts follow Food and Drug Administration rejections for the company’s proposed allergy drug combining the active ingredients of Merck’s Singulair and Schering-Plough Corp.’s Claritin.
The FDA also rejected the company’s developing cholesterol drug Cordaptive, while publicly demanding the company clean up problems at its main vaccine plant.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
